Atomoxetine Hydrochloride Api
Applications
Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention span, hyperactivity, emotional lability, and …
Description
Atomoxetine hydrochloride API is a white to off-white crystalline powder, a selective norepinephrine reuptake inhibitor, primarily prescribed for attention deficit hyperactivity disorder (ADHD) treatment.
Preparation
In a further aspect, the invention provides atomoxetine hydrochloride, prepared by a process comprising: a) hydrolyzing (±)-atomoxetine oxalate with a base to form atomoxetine; b) reacting the atomoxetine with an enantiomerically pure organic acid to form a salt; c) hydrolyzing the salt with a base to form …
Chemical Properties
Atomoxetine hydrochloride API is a crystalline powder with high solubility in water, known for its role as a selective norepinephrine reuptake inhibitor used in the treatment of ADHD.
Definition
Atomoxetine hydrochloride belongs to the group of alpha-sympathomimetics. The drug inhibits the reuptake of norepinephrine and dopamine. It is used for the treatment of attention deficit hyperactivity disorder (ADHD).
Description
| Product Name | Atomoxetine Hydrochloride Api |
| Country of Origin | Made in India |
| Usage | Pharma |
| Protein binding | 98% |
| Molecular Weight | 291.8 g/mol |
| Formula | C17H22ClNO |
| Melting point | 167-169°C |
| Flash point | 9℃ |
| storage temp. | 2-8°C |
| solubility | soluble in Methanol |
| form | solid |
| pka | 10.13(at 25℃) |
| color | White to Almost white |
| Water Solubility | Soluble to 50 mM in water with gentle warming |
| Water Solubility | Soluble to 50 mM in water with gentle warming |
| Packaging Size | As Per Requirement |
Our Export Location as a Atomoxetine Hydrochloride Api Manufacturer, Supplier, Exporter, Stockist from India.
 Afghanistan
|
 Bosnia and Herzegovina
|
 Cote d’Ivoire
|
 Schaumburg-Lippe*
|
 India
|
Albania
Algeria
Andorra
Angola
Antigua and Barbuda
Argentina
Armenia
Australia
Austria
Austrian Empire
Azerbaijan
Baden
Bahamas
Bahrain
Bangladesh
Barbados
Bavaria
Belarus
Belgium
Belize
Benin (Dahomey)
Bolivia
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Mauritania
Mauritius
Mecklenburg-Schwerin
Mecklenburg-Strelitz
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Botswana
Brazil
Brunei
Brunswick and Lüneburg
Bulgaria
Burkina Faso 
Burma
Burundi
Cabo Verde
Cambodia
Cameroon
Canada
Cayman Islands
Central African Republic
Central American Federation
Chad
Chile
China
Colombia
Comoros
Congo Free State
Costa Rica
Morocco
Mozambique
Namibia
Nassau
Nauru
Nepal
Netherlands
New Zealand
Nicaragua
Niger
Nigeria
North German Confederation
North German Union
North Macedonia
Norway
Oldenburg
Oman
Orange Free State
Pakistan
Palau
Panama
Papal States
Croatia
Cuba
Cyprus
Czechia
Democratic Republic of the Congo
Denmark
Djibouti
Dominica
Dominican Republic
Duchy of Parma
East Germany
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Eswatini
Ethiopia
Federal Government of Germany
Fiji
Papua New Guinea
Paraguay
Peru
Philippines
Piedmont-Sardinia
Poland
Portugal
Qatar
Republic of Genoa*
Republic of Korea (South Korea)
Republic of the Congo
Romania
Russia
Rwanda
Saint Kitts and Nevis
Saint Lucia
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Finland
France
Gabon
Gambia
Georgia
Germany
Ghana
Grand Duchy of Tuscany
Greece
Grenada
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Hanover
Hanseatic Republics
Hawaii
Hesse
Holy See
Honduras
Hungary
Iceland
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Texas
Thailand
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kingdom of Serbia/Yugoslavia
Kiribati
Korea
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Lew Chew (Loochoo)
Timor-Leste
Togo
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Tuvalu
Two Sicilies*
Uganda
Ukraine
Union of Soviet Socialist Republics*
United Arab Emirates
United Kingdom
Uruguay
Uzbekistan
Vanuatu
Venezuela
Vietnam
Württemberg*
Yemen
Zambia
ZimbabweRelated products
-
- Sale!
- API and intermediate
Fexofenadine Hydrochloride
- ₹5,400.00
-
- Sale!
- API and intermediate
Ivermectin Powder
- ₹16,500.00
-
- Sale!
- API and intermediate
Ivabradine
- ₹208,000.00
Reviews
There are no reviews yet.